Oncology, answered.
This year at ASCO, we're showcasing groundbreaking research powered by our global real-world data, alongside the launch of Flatiron Telescope, our new AI-powered intelligence platform.
ASCO 2026
May 29 – June 2
Chicago, IL
Booth #21149
25 research acceptances
Arun Sujenthiran, MD, Clinical Lead and Senior Medical Director, Flatiron Health
Introducing Flatiron Telescope, our AI-powered intelligence platform
Visit our booth to experience a live demo of Flatiron Telescope and see how you can turn data into confident decisions faster than ever before.
Flatiron networking reception at Cindy’s Rooftop
Saturday, May 30, 2026
6:00-10:00 PM CT
Join us for an evening of networking, cocktails and hors d'oeuvres at our exclusive networking reception. RSVP is required.
Preview our research at ASCO 2026
Our accepted research demonstrates how high-quality real-world data, paired with deep clinical expertise and advanced analytics, can answer oncology's most complex questions and drive more confident decision-making.
Posters
From plenary to practice: a large language model (LLM)-based thematic analysis of landmark clinical trial discussions and factors influencing their real-world adoption
Author affiliations: Penn Medicine, Flatiron Health
Abstract Number: 1583
Poster Session: Care Delivery/Models of Care
Poster Board: 501
Date and Time: May 31, 2026, 9-12 PM
Prognostic value of post-operative circulating tumor DNA (ctDNA) in real-world treatment and outcomes among patients (pts) with muscle invasive (MIBC) and locally advanced (LA) bladder cancer (BC)
Author affiliations: Flatiron Health
Abstract Number: 4600
Poster Session: Genitourinary Cancer—Kidney and Bladder
Poster Board: 79
Date and Time: May 31, 2026, 9-12 PM
Real-world second-line treatment patterns and outcomes by platinum sensitivity in extensive-stage small cell lung cancer in the post-immunotherapy era
Author affiliations: Flatiron Health
Abstract Number: 8083
Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Board: 557
Date and Time: May 31, 2026, 9-12 PM
Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first-line induction and maintenance regimens in extensive-stage small cell lung cancer
Author affiliations: Jazz Pharmaceuticals, Nebraska Western Iowa Health Care System/University of Nebraska Medical Center, Flatiron Health
Abstract Number: 8093
Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Board: 567
Date and Time: May 31, 2026, 9-12 PM
A risk stratification schema for patients with non-small cell lung cancer with multiple organ metastases
Author affiliations: Yale School of Medicine, Dana-Farber Cancer Institute, Flatiron Health
Abstract Number: 11138
Poster Session: Quality Care/Health Services Research Track
Poster Board: 121
Date and Time: June 1, 2026, 9-12pm
Platinum re-challenge in platinum-resistant ovarian cancer: real-world patterns and outcomes
Author affiliations: Flatiron Health
Abstract Number: 5566
Poster Session: Gynecologic Cancer
Poster Board: 232
Date and Time: June 1, 2026, 9-12pm
Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)
Author affiliations: Gilead Sciences, IQVIA, Flatiron Health
Abstract Number: 1025
Poster Session: Breast Cancer—Metastatic
Poster Board: 139
Date and Time: June 1, 2026, 1:30-4:30 PM
Recurrence risk prediction using a large, multi-site observational dataset of patients with early breast cancer including early-onset disease
Author affiliations: Flatiron Health
Abstract Number: 547
Poster Session: Cancer—Local/Regional/Adjuvant
Poster Board: 32
Date and Time: June 1, 2026, 1:30-4:30 PM
Online publications
Digital twin models for counterfactual prediction in NSCLC: a validation study using clinical trial data
Author affiliations: Genentech, University of Pennsylvania, Flatiron Health
Abstract Number for Publication: e20517
Real-world treatment patterns and outcomes among patients with high-risk and very high-risk non-metastatic prostate cancer
Author affiliations: Flatiron Health
Abstract Number for Publication: e17120
Drivers of organotropism and patterns of metastatic progression in metastatic non-small cell lung cancer
Author affiliations: Yale School of Medicine, Dana-Farber Cancer Institute, Flatiron Health
Abstract Number for Publication: e20541
Real-world biomarker testing rates, targeted therapy use, and clinical outcomes in patients with advanced gastric or GEJ cancer in the United States
Author affiliations: Flatiron Health
Abstract Number for Publication: e16039